We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 17th:
Manning & Napier, Inc. : This investment manager has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 41.2% over the last 60 days.
Manning & Napier’s shares gained more than 100% over the last one month above the S&P 500’s increase of 19.8%. The company possesses a Momentum Score of A.
CytomX Therapeutics, Inc. (CTMX - Free Report) : This oncology-focused biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.2% over the last 60 days.
Chembio Diagnostics, Inc. : This point-of-care diagnostic tests manufacturer has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.1% over the last 60 days.
AudioEye, Inc. (AEYE - Free Report) : This Web accessibility solutions provider has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 35.4% over the last 60 days.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Top Ranked Momentum Stocks to Buy for April 17th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 17th:
Manning & Napier, Inc. : This investment manager has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 41.2% over the last 60 days.
Manning & Napier, Inc. Price and Consensus
Manning & Napier, Inc. price-consensus-chart | Manning & Napier, Inc. Quote
Manning & Napier’s shares gained more than 100% over the last one month above the S&P 500’s increase of 19.8%. The company possesses a Momentum Score of A.
Manning & Napier, Inc. Price
Manning & Napier, Inc. price | Manning & Napier, Inc. Quote
CytomX Therapeutics, Inc. (CTMX - Free Report) : This oncology-focused biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.2% over the last 60 days.
CytomX Therapeutics, Inc. Price and Consensus
CytomX Therapeutics, Inc. price-consensus-chart | CytomX Therapeutics, Inc. Quote
CytomX Therapeutics’ shares gained more than 100% over the last one month. The company possesses a Momentum Score of A.
CytomX Therapeutics, Inc. Price
CytomX Therapeutics, Inc. price | CytomX Therapeutics, Inc. Quote
Chembio Diagnostics, Inc. : This point-of-care diagnostic tests manufacturer has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.1% over the last 60 days.
Chembio Diagnostics, Inc. Price and Consensus
Chembio Diagnostics, Inc. price-consensus-chart | Chembio Diagnostics, Inc. Quote
Chembio Diagnostics’ shares gained more than 100% over the last one month. The company possesses a Momentum Score of B.
Chembio Diagnostics, Inc. Price
Chembio Diagnostics, Inc. price | Chembio Diagnostics, Inc. Quote
AudioEye, Inc. (AEYE - Free Report) : This Web accessibility solutions provider has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 35.4% over the last 60 days.
Audioeye, Inc. Price and Consensus
Audioeye, Inc. price-consensus-chart | Audioeye, Inc. Quote
AudioEye’s shares gained more than 100% over the last one month. The company possesses a Momentum Score of B.
Audioeye, Inc. Price
Audioeye, Inc. price | Audioeye, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>